Enhertu approved in the US for HER2-low mBC
08 August 2022 07:00 BST Enhertu approved in the US as the first HER2-directed therapy for patients with HER2-low metastatic breast cancer Based on DESTINY-Breast04 results which showed AstraZeneca and Daiichi Sankyo's Enhertu reduced risk of disease progression or death by 50% and increased overall survival by more than six months versus chemotherapy AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients with unresectable or metastatic HER2-low (IHC 1+ or IHC 2+/ISH-) breast cancer who have received a